Deriving Patient Preferences: Project Transform

[LaurenH]

The treatment landscape of non-small cell lung cancer (NSCLC) is rapidly evolving, with the development of genetically targeted therapies and immunotherapy. Since 2015, the US Food and Drug Administration (FDA) has approved nine new drugs for the treatment of NSCLC, three reapprovals, and six new indications for an existing treatment. However, the side effects and toxicities of these treatments can be significant.

With the emergence of new treatment options for lung cancer, the complexity of treatment decisions for people living with lung cancer has increased. With these treatment options come unaddressed questions: What do patients really want from their treatment? Better quality of life? Extended survival? Other benefits?

With this in mind, LUNGevity launched Project Transform in partnership with Johns Hopkins School of Public Health, to focus on developing and applying novel methods (eg, discrete-choice experiments) to scientifically quantify patient preferences for the benefits and risks of treatments for lung cancer.

The results obtained from this initiative will be used to inform regulators, industry, and clinicians of the preferences of people living with lung cancer.

Your Voice Matters! LUNGevity wants to learn more about what patients (and their caregivers) want from their treatments. Please take this quick survey: https://www.lungevity.org/research/patient-focused-research-center-patient-force/deriving-patient-preferences-project-3